Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/69587
Título
Treatment of primary nummular headache: a series of 183 patients from the NUMITOR study
Autor
Año del Documento
2022
Editorial
MDPI
Descripción
Producción Científica
Documento Fuente
Journal of Clinical Medicine, 2023, Vol. 12, Nº. 1, 122
Resumen
Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT 05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters’ diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9–25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH.
Materias (normalizadas)
Headache
Cefalea
Headache - Treatment
Cefalea - Tratamiento
Head - Diseases
Cabeza - Enfermedades
Nervous system - Diseases - Treatment
Nervioso, Sistema - Enfermedades - Tratamiento
Medicine
Neurology
Materias Unesco
32 Ciencias Médicas
3205.07 Neurología
ISSN
2077-0383
Revisión por pares
SI
Patrocinador
Junta de Castilla y León, Gerencia Regional de Salud (SACYL) - (grant GRS 2416/A/21)
Version del Editor
Propietario de los Derechos
© 2022 The authors
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Aparece en las colecciones
Ficheros en el ítem
![Atribución 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-by.png)